摘要
目的 观察并探讨痰热清注射液治疗急性上呼吸道感染(acute upper respiratory tract infection, AURTI)的最佳配液浓度范围.方法 将符合入选标准的531例AURTI患者按痰热清注射液不同稀释倍数进行分组.将稀释倍数设定为10~25倍,以每增加2.5个稀释单位为一组,分为A组(10.0≤X<1.0︰12.5)、B组(12.5≤X<1.0︰15.0)、C组(1.0︰15≤X<1.0︰17.5)、D组(1.0︰17.5≤X<1.0︰20.0)、E 组(1.0︰20.0≤X<1.0︰22.5)和 F 组(1︰22.5≤X<1︰25.0).以临床有效率和不良反应发生率作为与浓度相关的临床考察指标,采用Origin 8软件建立两者与浓度组中值的关系,获取净效益指标.通过对净效益极大值的判断与获取以获得最佳配液浓度范围.结果 建立了临床有效率与浓度组中值的拟合关系:Y=-0.3+31.58X-203.33X2(R2=0.988 46),不良反应发生率与浓度组中值的拟合关系:Y=-0.27+10.24X-67.85X2(R2=0.982 28),净效益与浓度组中值的拟合关系:ΔY=-0.03+21.34X-135.48X2.根据净效益与浓度组中值的拟合关系得净效益峰值为0.81,浓度组中值为0.078 8,最佳稀释比例为1︰11.6~1︰14.1.结论 痰热清注射液最佳配液浓度范围为11.6~14.1 ml,即1 ml痰热清注射液用11.6~14.1 ml的溶媒稀释.
Objective To explore the optimal concentration of Tanreqing injection for acute upper respiratory tract infections. Methods A retrospective analysis of 531 children with acute upper respiratory tract infection treated with Tanreqing injection was conducted. These children were divided into different groups according to concentration of Tanreqing injection (i.e., the relationship between liquid and solvent, or the dilution ratio of solvent to liquid). Assume that X was the dilution ratio of solvent to liquid and the group was divided by an additional increment of 2.5 dilution units. All the children were divided into six groups as follows, groups of A (1:10≤X<1:12.5), B (1:12.5≤X<1:15), C (1:15≤X<1:17.5), D (1:17.5≤X<1:20), E (1:20≤X<1:22.5) and F (1:22.5≤X<1:25). The clinical effective rate and incidence of adverse reactions in each group were used as clinical indicators related to concentration of Tanreqing injection. Origin 8 was used to establish the relationship between the two indicators and the median of the concentration, and to seek a net benefit index that can combine the two indicators together. Finally, the relationship between the net benefit indicator and the median of the concentration were established, and the optimal concentration was found by judging and picking up the maximum of the net benefit indicator. Results The relationship between the clinical effective rate and the concentration median were: Y=-0.3+31.58X-203.33X2 (R2=0.988 46), and relationship between the incidence of adverse reactions and the concentration median were: Y=-0.27+10.24X-67.85X2 (R2=0.982 28), and relationship between the net benefit indicator and the concentration median were: ΔY=-0.03+21.34X-135.48X2. The peak value of the net benefit indicator was 0.81, and the corresponding median of the concentration was 0.078 8, and the optimal dilution ratio of liquid to solvent was 1:11.6-1:14.1. Conclusions This article explored the optimum concentration range of Tanreqing injection and gave tips for clinical safety and effective drug use.
作者
符珏
Fu Jue(Department of Pharmacy,Xiangtan Central Hospital,Xiangtan 411100,China)
出处
《国际中医中药杂志》
2019年第9期958-963,共6页
International Journal of Traditional Chinese Medicine
关键词
痰热清注射液
呼吸道感染
净效益/浓度
数学模型
配液浓度
Tan Re Qing Zhu She Ye
Respiratory tract infections
Net benefit/concentration
Mathematical model
Preparation concentration
